Trial Profile
Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 19 Dec 2019 Status changed from not yet recruiting to recruiting.
- 21 Jun 2017 New trial record